全文获取类型
收费全文 | 198941篇 |
免费 | 54163篇 |
国内免费 | 6690篇 |
专业分类
耳鼻咽喉 | 2615篇 |
儿科学 | 6071篇 |
妇产科学 | 3456篇 |
基础医学 | 28472篇 |
口腔科学 | 7566篇 |
临床医学 | 27815篇 |
内科学 | 41914篇 |
皮肤病学 | 8872篇 |
神经病学 | 19069篇 |
特种医学 | 6275篇 |
外国民族医学 | 42篇 |
外科学 | 26299篇 |
综合类 | 19650篇 |
现状与发展 | 20篇 |
一般理论 | 37篇 |
预防医学 | 13333篇 |
眼科学 | 4693篇 |
药学 | 18789篇 |
120篇 | |
中国医学 | 7638篇 |
肿瘤学 | 17048篇 |
出版年
2024年 | 313篇 |
2023年 | 1598篇 |
2022年 | 4040篇 |
2021年 | 6708篇 |
2020年 | 8900篇 |
2019年 | 13996篇 |
2018年 | 13619篇 |
2017年 | 14705篇 |
2016年 | 14949篇 |
2015年 | 16705篇 |
2014年 | 18107篇 |
2013年 | 18744篇 |
2012年 | 14019篇 |
2011年 | 14714篇 |
2010年 | 16031篇 |
2009年 | 11173篇 |
2008年 | 9741篇 |
2007年 | 8559篇 |
2006年 | 8197篇 |
2005年 | 7349篇 |
2004年 | 5503篇 |
2003年 | 5058篇 |
2002年 | 4389篇 |
2001年 | 3879篇 |
2000年 | 3564篇 |
1999年 | 2913篇 |
1998年 | 1367篇 |
1997年 | 1251篇 |
1996年 | 1029篇 |
1995年 | 982篇 |
1994年 | 921篇 |
1993年 | 526篇 |
1992年 | 915篇 |
1991年 | 822篇 |
1990年 | 687篇 |
1989年 | 580篇 |
1988年 | 540篇 |
1987年 | 455篇 |
1986年 | 368篇 |
1985年 | 289篇 |
1984年 | 187篇 |
1983年 | 171篇 |
1982年 | 97篇 |
1981年 | 94篇 |
1979年 | 142篇 |
1978年 | 114篇 |
1977年 | 84篇 |
1974年 | 95篇 |
1973年 | 73篇 |
1972年 | 88篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
M.‐Q. Man L. Ye L. Hu S. Jeong P. M. Elias C. Lv 《Clinical and experimental dermatology》2019,44(6):654-657
While therapeutic approaches for psoriasis are widely available, preventive regimens are lacking. We aimed to determine whether improvements in epidermal function could prevent psoriasis relapse. Two self‐controlled cohort studies were designed, enrolling two cohorts of patients with psoriasis (n = 30 and n = 60) to be treated topically with an in‐house‐prepared emollient or ATOPALM® cream applied twice daily to one forearm for 20 and 30 days, respectively, while the same sites on the contralateral arm served as the untreated control. Epidermal function on both arms was assessed prior to and at the end of the trials. Delayed relapse on the treated arm was seen in 54.5% and 71% of patients in the first and second cohort, respectively. The time of psoriatic relapse correlated with the extent of abnormalities in baseline epidermal function. These results suggest that improvements in epidermal function with topical emollients can prevent/attenuate the development of psoriasis. 相似文献
92.
93.
94.
95.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
96.
Leyi Wang Saraswathi Lanka Debbie Cassout Nohra E. Mateus‐Pinilla Ganwu Li William C. Wilson Dongwan Yoo Paul Shelton Richard L. Fredrickson 《Transboundary and Emerging Diseases》2019,66(5):1809-1820
First described in 1955 in New Jersey, epizootic haemorrhagic disease (EHD) causes a severe clinical disease in wild and domestic ruminants worldwide. Epizootic haemorrhagic disease outbreaks occur in deer populations each year from summer to late autumn. The etiological agent is EHD virus (EHDV) which is a double‐stranded segmented icosahedral RNA virus. EHD virus utilizes point mutations and reassortment strategies to maintain viral fitness during infection. In 2018, EHDV serotype 2 was predominantly detected in deer in Illinois. Whole genome sequencing was conducted for two 2018 EHDV2 isolates (IL41747 and IL42218) and the sequence analyses indicated that IL42218 was a reassortant between different serotypes whereas IL41747 was a genetically stable strain. Our data suggest that multiple strains contribute to outbreaks each year. 相似文献
97.
98.
99.
100.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献